Figure 1.

Flowchart of the study. FQ, fluoroquinolone; IDT, intradermal testing

^a96/163 (59%) were IDT positive by criteria #1; 53/163 (33%) by criteria #2; and 36/163 (22%) by criteria #3 at either 0.005 mg/L or 0.025 mg/mL for at least 1 FQ

^b47/82 (57%) were positive by criteria #1; 27/82 (29%) by criteria #2; and 29/82 (35%) by criteria #3 at either 0.005 mg/L or 0.025 mg/mL for at least 1 FQ. For greater detail on index reaction type, severity, and FQ; oral challenge FQ; subsequent treatment FQ, please see Table E2 (available in this article’s Online Repository at www.jaci-inpractice.org)

^cThese 77 patients did not undergo OC as a result of time constraints in clinic due to our prioritized testing of beta-lactam and sulfa allergies first. All of these 77 patients, if they were to return to clinic in the future, would qualify for FQ oral challenge.

^d30 were to ciprofloxacin, 17 to levofloxacin, 2 to moxifloxacin and 15 to at least 1 index FQ in patient with allergy history to ≥ 2 FQ.

^eThe 18 patients who underwent oral challenge to an alternative FQ did so earlier on in the development of this FQ testing strategy due to a cautious evolution of our routine clinical care. Of these 18 patients, 4 reported an index reaction history of anaphylaxis or multisystem involvement compatible with anaphylaxis and 2 reported an immediate reaction consisting of urticaria.